Compare MOLN & FMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MOLN | FMAC |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.3M | 157.5M |
| IPO Year | 2021 | 2026 |
| Metric | MOLN | FMAC |
|---|---|---|
| Price | $3.90 | $9.98 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | ★ 9.8K | 6.0K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.41 | $9.95 |
| 52 Week High | $5.36 | $10.02 |
| Indicator | MOLN | FMAC |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 45.32 |
| Support Level | $3.62 | $9.95 |
| Resistance Level | $3.96 | N/A |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.60 | 14.29 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.